
    
      A non randomized study ,plans to enrollment 24 subjects of B cell lymphoma .The subjects will
      divide into low, medium and high dose groups，to evaluate the safety and tolerability of
      CD19-CD22 CAR - T cells，to evaluate the preliminary efficacy and observe PK/PD parameters of
      CD19-CD22 CAR -T cells immunotherapy in patients with relapsed or refractory B cell lymphoma
      .
    
  